Compare HOVR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | PYXS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.5M | 71.6M |
| IPO Year | N/A | N/A |
| Metric | HOVR | PYXS |
|---|---|---|
| Price | $1.79 | $1.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.50 | ★ $6.75 |
| AVG Volume (30 Days) | ★ 924.2K | 548.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.83 |
| 52 Week High | $4.18 | $5.55 |
| Indicator | HOVR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 38.56 |
| Support Level | $1.69 | $1.27 |
| Resistance Level | $1.94 | $1.39 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 17.59 | 25.01 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.